Insight Molecular Diagnostics Secures $26M for GraftAssure Transplant Diagnostics Expansion
Insight Molecular Diagnostics raised $26.0 million by selling 4.525 million shares (or pre-funded warrants) at $5.75 per share in a registered direct offering. Net proceeds will fund R&D to expand its GraftAssure diagnostics beyond kidney into heart transplant rejection testing.
1. Offering Details
Insight Molecular Diagnostics entered into agreements to sell 4,525,976 shares of common stock (or pre-funded warrants) at $5.75 per share, raising approximately $26.0 million gross in a registered direct offering expected to close on February 12, 2026.
2. Use of Proceeds
The company plans to use net proceeds for general corporate purposes, principally to advance research and development in its transplantation diagnostics category, targeting expansion of the GraftAssure platform beyond kidney transplant rejection testing.
3. Investor Participation
Lake Street Capital Markets served as sole placement agent for the offering, and Bio-Rad Laboratories, a significant existing shareholder, participated on the same terms as other institutional investors.
4. Strategic Outlook
The funding bolsters Insight Molecular Diagnostics’ cash runway and supports strategic growth into heart transplant diagnostics, potentially enhancing its competitive position in molecular transplant testing markets.